Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Bead-Based Capture Kit Eases Enrichment and Cleanup of DNA Libraries

By BiotechDaily International staff writers
Posted on 13 Jun 2013
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
A newly released bead-based capture system was designed to provide genomic researchers with a sensitive and robust method for capture and purification of DNA sample libraries enabling high-quality targeted sequencing results.

NimbleGen (Madison, WI, USA), the genomics products subsidiary of Roche (Basel, Switzerland), recently announced the global launch of its SeqCap EZ Pure Capture Bead Kit.

This kit offers researchers a set of capture and purification beads used to prevent secondary capture and isolate DNA sample libraries from contaminants during amplification. It, therefore, represents a sensitive and robust method for cleanup of DNA sample libraries for high-quality DNA sequencing results


The kit includes SeqCap EZ Capture Beads and SeqCap EZ Purification Beads. Capture beads are used to recover the captured DNA sample from the hybridization of the DNA sample library and the SeqCap EZ Library. Purification beads are used to purify the amplified DNA sample library and the amplified capture DNA sample library after LM-PCR (ligase mediated - polymerase chain reaction). Roche provides a comprehensive set of reagents and probe pools for superior target enrichment performance. The probe pools include exome libraries, gene panels, and custom designs.

In addition to the SeqCap EZ Capture Beads Kit, Roche NimbleGen has released new disease-specific target enrichment panels for clinical research applications. These include the SeqCap EZ Comprehensive Cancer Design, which covers 578 genes implicated in a wide range of common and rare cancers, and the SeqCap EZ Neurology Panel Design, which covers 256 genes associated with 87 neurological disorders, including Parkinson’s disease, Alzheimer’s disease, epilepsy, and autism.


Related Links:

NimbleGen
Roche


comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.